Kenneth J. Valenzano
Amicus Therapeutics (United States)(US)
Publications by Year
Research Areas
Lysosomal Storage Disorders Research, Receptor Mechanisms and Signaling, Trypanosoma species research and implications, Glycogen Storage Diseases and Myoclonus, Neuropeptides and Animal Physiology
Most-Cited Works
- → Differential Regulation of the Dopamine D2and D3 Receptors by G Protein-coupled Receptor Kinases and β-Arrestins(2001)305 cited
- → Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy(2005)283 cited
- → Role of Dopamine Transporter in Methamphetamine-Induced Neurotoxicity: Evidence from Mice Lacking the Transporter(1998)268 cited
- → N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: II. In Vivo Characterization in Rat Models of Inflammatory and Neuropathic Pain(2003)260 cited
- → N-(4-Tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2 H)-carbox-amide (BCTC), a Novel, Orally Effective Vanilloid Receptor 1 Antagonist with Analgesic Properties: I. In Vitro Characterization and Pharmacokinetic Properties(2003)249 cited
- → Increased Methamphetamine Neurotoxicity in Heterozygous Vesicular Monoamine Transporter 2 Knock-Out Mice(1999)244 cited
- → Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders(2015)228 cited
- → The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat(2016)207 cited
- → Pharmacological Chaperones as Therapeutics for Lysosomal Storage Diseases(2013)206 cited
- → The pharmacological chaperone 1‐deoxygalactonojirimycin increases α‐galactosidase A levels in Fabry patient cell lines(2009)169 cited